Overcoming primary non-response to infliximab in ulcerative colitis: monocyte-derived PTGS2 as a therapeutic target
BackgroundPrimary non-response (PNR) to infliximab (IFX) remains a major therapeutic challenge in ulcerative colitis (UC). However, the molecular mechanisms underlying this treatment failure remains unelucidated. Therefore, there is an urgent need to i…